Outcomes of Patients with Metastatic Melanoma-A Single-Institution Retrospective Analysis.
Lidia SzatkowskaJan SieczekKatarzyna TekielaMarcin ZiętekPaulina Stachyra-StrawaPaweł CisekRafał Adam MatkowskiPublished in: Cancers (2022)
Patients with the V600 mutation should be closely monitored. In the event of disease recurrence, treatment with BRAF/MEK inhibitors should be considered. The type of treatment used has no effect on OS.